It's unclear how Catalent will proceed or whether it's receptive to a takeover offer, Bloomberg reported citing people familiar with the matter. Danaher and Catalent deal could be one of the ...
Danaher's approach to Catalent values it at a significant premium, the report said, adding that unclear how Catalent will proceed or whether it is receptive to a takeover offer. A deal is not ...
Notably, Bloomberg earlier this month reported that Danaher was interested in acquiring life sciences firm Catalent (CTLT). Although the initial reaction to this news was mixed, the market should ...
UKRAINE - 2021/05/04: In this Photo illustration a Catalent logo of a pharmaceutical company is seen ... [+] on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images ...
(Bloomberg) -- Life sciences company Danaher Corp. has expressed takeover interest in contract manufacturer Catalent Inc., according to people familiar with the matter. Most Read from Bloomberg ...
Danaher (DHR) stock is rising after the company announced it will acquire Pall Corp. (PLL) and split itself into two companies. Danaher (DHR) stock is rising after the company announced it will ...
Pall Corp. (PLL) stock is rising after the company said it will be acquired by Danaher (DHR) for $13.8 billion. Pall Corp. (PLL) stock is rising after the company said it will be acquired by ...
It brings to an end one of the most hotly-contested takeover battles in recent UK corporate history, involving private investors and all the major supermarket groups. Bradford-based Morrisons ...
Shares of Catalent CTLT gained 19.5% on Monday on rumors of a potential acquisition by a life sciences company — Danaher DHR. The CTLT stock started its upward journey during pre-market trading on Feb ...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Catalent To Contact Him Directly To Discuss Their Options New York, New York ...
Life sciences and medical diagnostics company Danaher (DHR) reported better-than-expected earnings and revenue for the fourth quarter. We view the dip in the stock as unjustified and an opportunity.
